The time for Edmund Andre to bring a suit against the maker of thalidomide has long since passed, a federal judge in Philadelphia has ruled, rejecting Andre’s expert and the argument that the company’s initial cover-up of the drug’s effect on babies born to women who took it would extend the statute of limitations.
Andre, who was born in 1957 with severe birth defects, was among about 50 plaintiffs who brought claims against GlaxoSmithKline in recent years. They are all represented by the Seattle class-action law firm Hagens Berman Sobol Shapiro, according to the opinion from U.S. District Judge Paul S. Diamond of the Eastern District of Pennsylvania.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
